Latest updates on chronic viral hepatitis B

Abstract

Hepatitis B virus (HBV) remains a major cause of liver-relatedmorbidity and mortality in Turkey and all over the world. Twodifferent types of antiviral agents can be used in the treatmentof chronic hepatitis B (CHB). Conventional (IFN) or pegylatedinterferon alpha (PegIFN), nucleoside [lamivudine (LMV),telbivudine, emtricitabine, entecavir (ETV)] and nucleotide analogs[adefovir dipivoxil (ADV)] and tenofovir disoproxil fumarate(TDF)]. Antiviral agent must ensure a degree of HBV viralsuppression and will lead to biochemical, serological remissionand histological improvement. Current treatment strategies arediscussed in present brief report.Keywords: Chronic hepatitis B, Nucleos(t)ide analog, Entecavir,Tenofovir disoproxil fumarate

References

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global
2. epidemiology of hepatitis B virus infection: new estimates of
3. age-specific HBsAg seroprevalence and endemicity. Vaccine
4. 30:2212-19, doi: 10.1016.
5. Tozun N, Ozdogan OC, Cakaloğlu Y, et al. Seroprevalence of
6. hepatitis B and C virus infections and risk factors in Turkey
7. a fieldwork TURHEP study, Clin Microbiol Infect. 2015
8. Nov;21:1020-6. doi: 10.1016/j.cmi.2015.06.028.

9. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology
10. 45:507–39.
11. EASL Clinical Practice Guidelines: Management of chronic
12. hepatitis B virus infection. J Hepatol 2012;57: 167-85. doi
13. 1016/j.jhep.2012.02.010.
14. Lok A, McMahon B, Brown R, et al. Antiviral therapy for
15. chronic hepatitis B virus infection in adults: a systematic
16. review and meta-analysis. Hepatology 2015;63:284-306.
17. doi: 10.1002/hep.28280
18. Terrault NA, Bzowej NN, Kyong MS, Hwang JP, Jonas PP
19. Murad MH. AASLD Guidelines for Treatment of Chronic
20. Hepatitis B. Hepatology 2016;6:261-83. doi: 10.1002/
21. hep.28156
22. Chaung KT, Ha NB, Trinh HN, et al. High frequency of
23. recurrent viremia after hepatitis B e antigen seroconversion
24. and consolidation therapy. J Clin Gastroenterol 2012;46:865-
25. doi: 10.1097/MCG.0b013e31825ceed9
26. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D
27. Hadziyannis E. Sustained responses and loss of HBsAg in
28. HBeAg-negative patients with chronic hepatitis B who
29. stop long-term treatment with adefovir. Gastroenterology
30. 143:629-36.e, doi: 10.1053/j.gastro.2012.05.039.
31. Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C
32. Michielsen PP, et al. Peginterferon alpha-2b is safe and
33. effective in HBeAg-positive chronic hepatitis B patients with
34. advanced fibrosis. Hepatology 2007;46:388–94.
35. Schiff E, Simsek H, Lee WM, et al. Efficacy and safety
36. of entecavir in patients with chronic hepatitis B and
37. advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol
38. 103:2776–83. doi: 10.1111/j.1572-0241.2008.02086.
39. Buti M, Hadziyannis S, Mathurin P, et al. Tenofovir
40. disoproxil fumarate is highly active for treatment of chronic
41. hepatitis B in subjects with cirrhosis. J Hepatol 2008;48:S33.
42. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir
43. therapy results in the reversal of fibrosis/cirrhosis and
44. continued histological improvement in patients with chronic
45. hepatitis B. Hepatology 2010;52:886–93. doi: 10.1002/
46. hep.23785.
47. Idilman R, Gunsar F, Koruk M, et al. Long-term entecavir
48. or tenefovir disoproxil fumarate therapy in treatment-naive
49. chronic hepatitis B patients in the real-world setting. J Viral
50. Hepatit 2015;22:504-10 doi:10.1111/jvh.12358.
51. Papatheodoridis GV, Lampertico P, Manolakopoulos S
52. Lok A. Incidence of hepatocellular carcinoma in chronic
53. hepatitis B patients receiving nucleos(t)ide therapy: a
54. systematic review. J Hepatol 2010;53:348–56, doi: 10.1016/j.
55. jhep.2010.02.035.
56. Cornberg M, Protzer U, Petersen J, et al. Prophylaxis
57. diagnosis and therapy of hepatitis B virus infection – the
58. German guideline. Z Gastroenterol 2011;49:871–930. doi
59. 1055/s-0031-1273462.